Printer Friendly

Pharma R&D spending in Q3.

R&D spending by the top 10 pharmaceutical companies showed a double-digit rise for the third quarter of 2002. Lead by double-digit increases in spending by AstraZeneca, Merck. Novartis and Pharmacia, spending by the top 10 pharmaceutical companies increased 10.5% compared to the third quarter of 2001 to more than $6.9 billion. Sequentially, the trend is also upwards as these same companies showed only a 7.5% increase in R&D spending for the first half of 2002 (see IBO 7/31/02).

For the quarter, total R&D spending by the top 10 pharmaceutical companies rose faster than sales, up 10.5% compared to a 6.8% increase in sales year over year. However, two companies, Wyeth and Bristol-Myers Squibb showed a drop in sales. Total sales for the top 10 pharmaceutical companies were $59.5 billion for the third quarter.

As for R&D as a percentage of sales, spending levels were nearly the same year over year for the third quarter. For the top 10 pharmaceutical companies, R&D as a percentage of sales rose only 0.4% for the third quarter. The only company to show an increase above 2% was Bristol-Myers Squibb at 2.5%, and only three companies, AstraZeneca, Wyeth and Pharmacia, showed an increase of over 1%.

Thus, it appears that there is an upward trend in R&D spending for the second half of the year. But changes are ongoing. GlaxoSmithKline noted that R&D spending will increase in the fourth quarter. However, the head of development at its pharmaceutical group left to join Bristol-Myers Squibb earlier this month. In its quarterly release, Novartis announced the implementation of a new research strategy.
Research & Development Expenses

 2002 2001 Growth
 Q3 Q3 from 2001

GlaxoSmithKilne $986 $922 6.9%
Novartis $717 $625 14.6%
Wyeth $518 $473 9.5%
Johnson & Johnson $952 $899 5.9%
Pharmacia $565 $507 11.4%
Bristol-Myers Squibb $542 $496 9.3%
AstraZeneca $757 $614 23.3%
Merck $677 $590 14.7%
Pfizer $1,263 $1,188 6.3%

TOTAL $6,977 $6,314 10.5%

Sales
 2002 2001 Growth
 Q3 Q3 from 2001

GlaxoSmithKilne $7,744 $7,191 7.7%
Novartis $5,364 $4,803 11.7%
Wyeth $3,623 $3,699 -2.1%
J&J $9,079 $8,058 12.7%
Pharmacia $3,579 $3,530 1.4%
Bristol-Myers Squibb $4,171 $4,743 -12.1%
AstraZeneca $4,350 $3,950 10.1%
Merck $12,893 $11,920 8.2%
Prizer $8,725 $7,824 11.5%

TOTAL $59,628 $55,718 6.8%
COPYRIGHT 2002 Strategic Directions International Inc. (SDI)
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2002 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:pharmaceutical companies
Publication:Instrument Business Outlook
Geographic Code:1USA
Date:Oct 31, 2002
Words:428
Previous Article:Random samples: products.
Next Article:Random samples: sales.
Topics:


Related Articles
Endpoint.
Pharmaceutical R&D: the sky is not falling.
Big pharma R&D operations make changes.
Big Pharma R&D spending grows 3.9% in first half.
Astellas Establishes New Subsidiary 'Astellas Pharma Chemicals Co., Ltd.'.
Big Pharma slims down.
GCC's only third party Pharma logistics company grabs attention of international industry giants at Lake Geneva, France summit.
Big pharma continues to make big changes.
IS COST CONTAINMENT IMPACTING PHARMACEUTICAL INNOVATION?

Terms of use | Privacy policy | Copyright © 2022 Farlex, Inc. | Feedback | For webmasters |